Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015, Article ID 672759, 10 pages
http://dx.doi.org/10.1155/2015/672759
Review Article

Emerging Roles of MicroRNAs in EGFR-Targeted Therapies for Lung Cancer

1Human Stem Cell Institute of the General Hospital, Ningxia Medical University, Yinchuan, Ningxia 750004, China
2Department of Thoracic Surgery of the General Hospital, Ningxia Medical University, Yinchuan, Ningxia 750004, China
3Center of Laboratory Medicine of the General Hospital, Ningxia Medical University, Yinchuan, Ningxia 750004, China
4Department of Clinical Oncology, Queen Elizabeth Hospital, Kowloon, Hong Kong
5Key Laboratory of Ministry of Education for Conservation and Utilization of Special Biological Resources in Western China, Ningxia University, Yinchuan, Ningxia 750021, China

Received 10 February 2015; Accepted 20 May 2015

Academic Editor: Martin Sebastian Staege

Copyright © 2015 Fei Han et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Lung cancer is a leading cause of cancer mortality worldwide. Several molecular pathways underlying mechanisms of this disease have been partly elucidated, among which the epidermal growth factor receptor (EGFR) pathway is one of the well-known signaling cascades that plays a critical role in tumorigenesis. Dysregulation of the EGFR signaling is frequently found in lung cancer. The strategies to effectively inhibit EGFR signaling pathway have been mounted for developing anticancer therapeutic agents. However, most anti-EGFR-targeted agents fail to repress cancer progression because of developing drug-resistance. Therefore, studies of the mechanisms underpinning the resistance toward anti-EGFR agents may provide important findings for lung cancer treatment using anti-EGFR therapies. Recently, increasing numbers of miRNAs are correlated with the drug resistance of lung cancer cells to anti-EGFR agents, indicating that miRNAs may serve as novel targets and/or promising predictive biomarkers for anti-EGFR therapy. In this paper, we summarize the emerging role of miRNAs as regulators to modulate the EGFR signaling and the resistance of lung cancer cells to anti-EGFR therapy. We also highlight the evidence supporting the use of miRNAs as biomarkers for response to anti-EGFR agents and as novel therapeutic targets to circumvent the resistance of lung cancer cells to EGFR inhibitors.